Literature DB >> 16409995

Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.

Aaron Juni1, Gad Klein, Benjamin Kest.   

Abstract

Hyperalgesia following chronic morphine treatment is thought to be a response to opioid receptor activation and analgesia and contribute to the development of analgesic tolerance. Here, the relationship between these variables was studied in mice tested for nociceptive sensitivity on the tail-withdrawal test during chronic infusion of various morphine doses. Hyperalgesic onset was preceded by dose-dependent analgesia except for the lowest morphine dose, which caused hyperalgesia 6 h after the start of infusion. Morphine ED50 values obtained at various infusion intervals demonstrated both analgesic tolerance in the absence of hyperalgesia and hyperalgesia in the absence of tolerance. Continuous opioid receptor antagonism using naltrexone pellets abolished analgesia during continuous morphine administration, transiently potentiated hyperalgesia, and revealed differences in hyperalgesic onset between morphine infusion doses. Acute injection of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 attenuated hyperalgesia in naltrexone-treated mice, demonstrating a role for this receptor in morphine hyperalgesia unrelated to its effects upon morphine analgesia. In mice where hyperalgesia subsided after continuous infusion of the highest morphine dose (i.e., hyperalgesic adaptation), hyperalgesia was restored after infusing the lower but not higher morphine dose. In addition, acute injection of morphine-3beta-glucoronide (M3G) caused hyperalgesia that was cross-adaptive with the lower morphine dose only. The data demonstrate that morphine hyperalgesia is independent of prior or concurrent opioid receptor activity or analgesia and is unrelated to analgesic tolerance. Furthermore, the lack of hyperalgesic cross-adaptation between high and low morphine doses, and their differential cross-adaptation with M3G hyperalgesia, also suggests distinct morphine dose-dependent hyperalgesic systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409995     DOI: 10.1016/j.brainres.2005.11.054

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 2.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.

Authors:  Caroline A Arout; Ellen Edens; Ismene L Petrakis; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

4.  Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor.

Authors:  Aaron Juni; Minying Cai; Magda Stankova; Amanda R Waxman; Caroline Arout; Gad Klein; Albert Dahan; Victor J Hruby; Jeffrey S Mogil; Benjamin Kest
Journal:  Anesthesiology       Date:  2010-01       Impact factor: 7.892

5.  Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats.

Authors:  Ahmad A Altarifi; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2014-12-18       Impact factor: 4.432

Review 6.  Ketamine for the Treatment of Chronic Pain: A Comprehensive Review.

Authors:  Jacob E Israel; Samantha St Pierre; Emily Ellis; Josephine S Hanukaai; Nazir Noor; Giustino Varrassi; Markus Wells; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-07-10

7.  Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.

Authors:  Maarten Swartjes; René A G Mooren; Amanda R Waxman; Caroline Arout; Koen van de Wetering; Jan den Hartigh; Jos H Beijnen; Benjamin Kest; Albert Dahan
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

8.  Increased spinal dynorphin contributes to chronic nicotine-induced mechanical hypersensitivity in the rat.

Authors:  Chris Lough; Tracey Young; Renee Parker; Shannon Wittenauer; Michelle Vincler
Journal:  Neurosci Lett       Date:  2007-06-08       Impact factor: 3.046

9.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

10.  Sex-dependent influences of morphine and its metabolites on pain sensitivity in the rat.

Authors:  H H Doyle; A Z Murphy
Journal:  Physiol Behav       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.